SCHEMBL17050437

SCHEMBL17050437

Oc1ccc(Oc2ncc(Br)s2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 7/20 0.36
ESR1 P03372 3/20 0.36
ESR2 Q92731 2/20 0.36
HSD17B10 Q99714 1/20 0.35
NR1I2 O75469 1/20 0.35
LMNA P02545 1/20 0.35
TTR P02766 1/20 0.35
PGR P06401 1/20 0.35
HSP90AA1 P07900 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
MAPT P10636 1/20 0.35
HSPA5 P11021 1/20 0.35
HPGD P15428 1/20 0.35
CBR1 P16152 1/20 0.35
TBXA2R P21731 1/20 0.35
SLC6A2 P23975 1/20 0.35
AGTR1 P30556 1/20 0.35
SLC6A3 Q01959 1/20 0.35
SNCA P37840 1/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12475820 0.80 ACACB (0.44) ACACBHPGDSLC6A2SLC6A3CYP2C9
SCHEMBL12476072 0.78 HTT (0.44) LMNAHPGDSLC6A2SLC6A3
SCHEMBL12475966 0.78 ACACB (0.45) ACACBHSD17B10MAPTCYP2C9CYP2C19
SCHEMBL12475997 0.77 ACACB (0.57) ACACBCYP2C9CYP2C19ACACA
SCHEMBL12476062 0.76 ACACB (0.55) ACACBMAPTCYP2C9CYP2C19ACACA
SCHEMBL5942840 0.74 MEN1 (0.45) ACACBESR1ESR2LMNAMAPT
SCHEMBL12475401 0.74 ACACB (0.55) ACACBHPGDCYP2C9CYP2C19ACACA
SCHEMBL12476320 0.74 ACACB (0.56) ACACBCYP2C9CYP2C19ACACA
SCHEMBL9623596 0.73 TTR (0.57) ESR1ESR2HSD17B10NR1I2LMNA
SCHEMBL4740349 0.73 ESR1 (0.41) ESR1ESR2HSD17B10NR1I2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3670496-A2 ACC2 INHIBITORS Shionogi&Co., Ltd. (JP) 2020-06-24 EP disclosed
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2016-09-08 US disclosed
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2016-09-08 US disclosed
EP-3059225-A1 NOVEL ALKYLENE DERIVATIVE Shionogi & Co., Ltd. (JP) 2016-08-24 EP disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE ACSS2, ACACB, ACAT2 ACACB 2/4885ESR1 1443/4885ESR2 355/4885
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES ACSS2, ACACB, ADCY2 ACACB 2/4885ESR1 1103/4885ESR2 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.